SkyePharma, the drug delivery group, has agreed a deal in which Mundipharma will be the European partner to market the asthma drug that it calls its “main lifeline”. The news will come as a relief to investors annoyed by the length of time that it has taken to find partners, which has fed the group’s losses. While the market sent SkyePharma’s shares up 1½p to 27p, there are still fears that Flutiform will have to compete with rivals’ drugs.